By Mina Lobbous, MD, MPH From: targetedonc.com This study (NCT03501979) investigated the drug combination of tucatinib (Tukysa), trastuzumab (Herceptin), and capecitabine for HER2-positive breast cancer with leptomeningeal metastases (LM). Treatment options for LM are limited, and survival rates are low. The researchers enrolled 17 patients with HER2-positive breast cancer and newly diagnosed LM. All patients received the drug combination in …
-
-
What Motivates You to Action After a Breast Cancer Diagnosis?
-
The 4th of July – Independence Day for This Breast Cancer Survivor
-
What Is Needed After Breast Cancer Surgery?
-
The Sadness Experienced by Some Breast Cancer Survivors
-
The Importance of Hope for Breast Cancer Survivors
